Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Molgramostim Nebulizer Solution Expanded Access Program Protocol
- Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Savara Inc.
- Registration Number
- NCT06546098
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
- Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
- Interventions
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Savara Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06431776
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Savara Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT04544293
- Locations
- 🇺🇸
University Of Arkansas For Medical Services, Little Rock, Arkansas, United States
🇺🇸UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
- Conditions
- Mycobacterium Infections, NontuberculousCystic Fibrosis (CF)
- Interventions
- Device: PARI eFlow nebulizer system
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Savara Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03597347
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸Central Florida Pulmonary Group, Orlando, Florida, United States
🇺🇸Northwell Health, New Hyde Park, New York, United States
Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Savara Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03482752
- Locations
- 🇩🇰
Dept. Of Respiratory Diseases & Allergy, Århus, Denmark
🇫🇷CHU Rennes Hospital Pontchaillou, Service de Pneumologie, Rennes, France
🇩🇪Ruhrlandklinik Essen Westdeutsches Lungenzentrum am Universitätsklinikum Essen GmbH, Essen, Germany
- Prev
- 1
- 2
- 3
- Next
News
Savara Reports 50% Increase in Autoimmune PAP Patient Population, Plans December 2025 FDA Resubmission for MOLBREEVI
Savara's updated health claims analysis identifies approximately 5,500 autoimmune PAP patients in the U.S., representing a 50% increase from the company's previous 2023 estimate of 3,600 patients.
Savara to Present Phase 3 IMPALA-2 Trial Data and Host aPAP Symposium at ERS Congress 2025
Savara Inc. will present three research abstracts at the European Respiratory Society Congress 2025, including new data from the Phase 3 IMPALA-2 trial of inhaled molgramostim for autoimmune pulmonary alveolar proteinosis.
Savara's Inhaled Molgramostim Shows 9.8% Lung Function Improvement in Phase 3 Autoimmune PAP Trial
Savara's Phase 3 IMPALA-2 trial demonstrated that inhaled molgramostim significantly improved lung function by 9.8% at 24 weeks compared to 3.8% with placebo in autoimmune pulmonary alveolar proteinosis patients.